engleski

Modifying the effects of cytoreductive drugs on kidney function in myeloproliferative neoplasms

This Letter is a comment on the retrospective study of Kwiatkowski et al, which has demonstrated that the use of anagrelide in patients with essential thrombocythemia (ET) may be associated with worsening of kidney function. In this Letter, we emphasize the clinical importance of chronic kidney disease in patients with myeloproliferative neoplasms and discuss the reasons which could have lead to an increased risk of kidney dysfunction in ET patients treated with anagrelide. Finally, we suggest the authors of the original study to perform additional analyses on their dataset.

cytoreductive drugs ; kidney function ; myeloproliferative neoplasms

nije evidentirano